Alvotech Ordinary Shares (ALVO) Stock: Buy, Sell, or Hold?
ALVO - Alvotech Ordinary Shares
$4.79
-0.34 (-6.63%)
▼
5d:
-9.79%
30d:
-17.56%
90d:
+56.54%
HOLD
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALVO trades at premium valuation expecting 6.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: ALVO trades at premium valuation expecting 6.5% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.55
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.44
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $4.79, which is considered oversold relative to its 30-day fair value range of $5.16 to $5.92. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.8) compared to its historical average (17.2). At these levels, the market is pricing in 6.5% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is currently testing key support at $4.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ALVO scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.20 (+50.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is currently testing key support at $4.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ALVO scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.20 (+50.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.16 -
$5.92
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 50.3% below Wall St target ($7.20)
- BULLISH: Expecting earnings turnaround to 6.5% growth with -38.9% revenue growth
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.16 -
$5.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.79
Resistance Level
$5.89
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.82
Wall Street Target
$7.20
(+50.3%)
Revenue Growth (YoY)
-38.9%
Earnings Growth (YoY)
-99.0%
Profit Margin
-36.3%
Valuation Premium vs History
+6.5% premium
PE vs Historical
20.8 vs 17.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.5%
(market-implied from PE analysis)
1-Year Target
$5.10
(+7%)
2-Year Target
$5.43
(+13%)
3-Year Target
$5.79
(+21%)
3-Yr Target (if PE normalizes)
(PE: 21→17)
PE COMPRESSION
$4.78
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 22, 2026 11:33 PM ET
Data refreshes hourly during market hours. Next update: 12:33 AM
Data refreshes hourly during market hours. Next update: 12:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
